Back

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Phenotypic approaches to heart failure treatment Ventricular Remodelling ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Matthew M Y Lee

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Tumor-driven cytokines IL-13 and IFN-γ ameliorate pressure overload–induced cardiac dysfunction
Ms L. Awwad (Haifa, IL)
Abstract
Presentation thumbnail
Investigating the role of neutrophils in trametinib-induced cardiomyopathy
Doctor S. Morrissey (Chapel Hill, US)
Abstract
Presentation thumbnail
Influence of invasive ischemic evaluation on mortality in patients with a new onset heart failure after myocardial infarction
Doctor M. Ferreira (Funchal, PT)
Abstract
Presentation thumbnail
The sugar alcohol sweeteners Erythritol and Xylitol are linked with heart failure
Doctor M. Witkowski (Berlin, DE)
Abstract
Presentation thumbnail
Somatic DNMT3A and TET2 mutations in explanted hearts from advanced heart failure show enrichment in myocarditis and inflammatory heart disease
Mrs S. Ramanathan (Gothenburg, SE)
Abstract

Access the full session

Session thumbnail
Phenotypic approaches to heart failure treatment

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis.
29 June 2021
thumbnail
Congress Presentation
Mineralocorticoid receptor antagonists after acute myocardial infarction in patients with mild to moderately reduced ejection fraction
22 May 2023
thumbnail
Congress Presentation
Metabolic impact of empagliflozin in patients with acute decompensated heart failure:A secondary analysis of the EMPAG-HF trial
20 May 2023
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources